<bill session="115" type="s" number="771" updated="2019-04-18T16:34:32Z">
  <state datetime="2017-03-29">REFERRED</state>
  <status>
    <introduced datetime="2017-03-29"/>
  </status>
  <introduced datetime="2017-03-29"/>
  <titles>
    <title type="official" as="introduced">A bill to improve access to affordable prescription drugs.</title>
    <title type="short" as="introduced">Improving Access To Affordable Prescription Drugs Act</title>
    <title type="short" as="introduced">Improving Access To Affordable Prescription Drugs Act</title>
    <title type="display">Improving Access To Affordable Prescription Drugs Act</title>
  </titles>
  <sponsor bioguide_id="F000457"/>
  <cosponsors>
    <cosponsor bioguide_id="B001230" joined="2017-03-29"/>
    <cosponsor bioguide_id="B001277" joined="2017-03-29"/>
    <cosponsor bioguide_id="B001288" joined="2017-03-29"/>
    <cosponsor bioguide_id="B000944" joined="2017-03-29"/>
    <cosponsor bioguide_id="D000563" joined="2017-03-29"/>
    <cosponsor bioguide_id="G000555" joined="2017-03-29"/>
    <cosponsor bioguide_id="H001076" joined="2017-03-29"/>
    <cosponsor bioguide_id="K000367" joined="2017-03-29"/>
    <cosponsor bioguide_id="M001176" joined="2017-03-29"/>
    <cosponsor bioguide_id="R000122" joined="2017-03-29"/>
    <cosponsor bioguide_id="S000033" joined="2017-03-29"/>
    <cosponsor bioguide_id="U000039" joined="2017-03-29"/>
    <cosponsor bioguide_id="V000128" joined="2017-03-29"/>
    <cosponsor bioguide_id="W000817" joined="2017-03-29"/>
    <cosponsor bioguide_id="W000802" joined="2017-03-29"/>
  </cosponsors>
  <actions>
    <action datetime="2017-03-29">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2017-03-29" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="115" relation="unknown" number="6340"/>
    <bill type="s" session="115" relation="unknown" number="252"/>
    <bill type="s" session="115" relation="unknown" number="348"/>
    <bill type="s" session="115" relation="unknown" number="469"/>
    <bill type="s" session="115" relation="unknown" number="3411"/>
    <bill type="s" session="115" relation="unknown" number="2478"/>
    <bill type="h" session="115" relation="identical" number="1776"/>
    <bill type="h" session="115" relation="unknown" number="1245"/>
    <bill type="s" session="115" relation="unknown" number="2476"/>
    <bill type="s" session="115" relation="unknown" number="1688"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Administrative remedies"/>
    <term name="Business records"/>
    <term name="Canada"/>
    <term name="Cancer"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Congressional oversight"/>
    <term name="Consumer affairs"/>
    <term name="Corporate finance and management"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Executive agency funding and structure"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Government trust funds"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health programs administration and funding"/>
    <term name="Income tax deductions"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Judicial review and appeals"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Research and development"/>
    <term name="Retail and wholesale trades"/>
    <term name="Trade restrictions"/>
    <term name="User charges and fees"/>
    <term name="Veterans' medical care"/>
  </subjects>
  <amendments/>
  <summary date="2017-03-29T04:00:00Z" status="Introduced in Senate">This bill amends provisions of various laws relating to prescription-drug pricing and affordability.&#160;Specifically, the bill:

 expands reporting requirements for drug manufacturers&#160;and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures; requires the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program; requires the GAO to report to Congress on such negotiations conducted by the CMS; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance,&#160;for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program; modifies provisions related to the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; establishes a prize fund for new and more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; modifies provisions related to drug exclusivity; allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.</summary>
  <committee-reports/>
</bill>
